Amyotrophic Lateral SclerosisNCT05003167
Effectiveness of Expiratory Muscle Strength Training for Improving Communication in ALS
A study testing Expiratory Muscle Strength Training (EMST-150) in people with Amyotrophic Lateral Sclerosis, run by Purdue University at 1 site in United States.
Trial summary
A tele-health treatment study for individuals with early stage ALS with the aim to improve communication, cough response, and respiratory strength. All participants complete a respiratory strength training program using an Expiratory Muscle Strength Training (EMST 150) device from the comfort of their homes for 6… Read more about this study
- Who is it for?
- Ages 40 to 70 years
- Conditions the study is for
- Amyotrophic Lateral Sclerosis
- What is being tested?
- Expiratory Muscle Strength Training (EMST-150)
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 13 participants
- Where
- 1 siteUnited States
- Study dates
- 1 Jan 2021to 1 Jun 2022
- Phase
- Interventional
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 40 to 70 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Diagnosis of ALS
- Within the early stages of disease progression (i.e., able to talk, breathe, and eat independently)
- Speaker of English
- Have a family member/caregiver willing to assist as needed
- Have access to an electronic device and internet for tele-health
Who cannot join
- A history of neurological disease (besides ALS)
- A history of asthma or respiratory problems (e.g., COPD, emphysema)
- A history of head, neck, or chest surgery (except mastectomy)
- A history of smoking within the last 5 years
- Reliance on mechanical ventilation (including CPAP)
Trial locations and contacts
1 site in 1 country.
About this study
A tele-health treatment study for individuals with early stage ALS with the aim to improve communication, cough response, and respiratory strength. All participants complete a respiratory strength training program using an Expiratory Muscle Strength Training (EMST 150) device from the comfort of their homes for 6 weeks.
Read the detailed description
The investigators are looking for people with early stage ALS to participate in a completely tele-health (no in-person visits required) treatment study examining the effects of an Expiratory Muscle Strength Training device (EMST-150) on communication, cough, and respiratory strength. Participants will be required to attend 2 virtual baseline assessment sessions followed by 12 additional virtual training sessions (2 per week for 6 weeks). Participants should plan to be actively enrolled in the study for ~10 weeks (3 weeks of baseline monitoring followed by 6 weeks of training). Participants will also be required to fill out a series of questionnaires assessing the EMST's effectiveness via tele-health.
- Conditions
- Amyotrophic Lateral Sclerosis
- Being tested
- Expiratory Muscle Strength Training (EMST-150)
- Medical subject headings
- Amyotrophic Lateral Sclerosis
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Expiratory Muscle Strength Training (EMST-150)Device
All participants will forcefully breathe out into an Expiratory Muscle Strength Training device (EMST-150) 25 times per day for 6 weeks. The EMST device will be set at a moderate intensity level (50% of each participant's maximum expiratory pressure).
| Study group | Role | What they receive |
|---|---|---|
| Expiratory Muscle Strength Training | Experimental | All participants will forcefully breathe out into an Expiratory Muscle Strength Training device (EMST-150) 25 times per day for 6 weeks. The EMST device will be set at a moderate intensity level (50% of each participant's maximum expiratory pressure). Receives: Device: Expiratory Muscle Strength Training (EMST-150) |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change From Baseline to Post-treatment for Maximum Expiratory Pressure
Change in expiratory muscle strength throughout the study duration measured by the participant blowing into a pressure meter
Measured: Baseline 2 (week 2), Pre-Training (week 3), and Post-Training (week 10)
Secondary outcomes (11)
Peak Expiratory Flow Rate
Change in cough strength (as measured by peak expiratory flow rate) throughout the study duration, measured using a flow meter that the participant coughs into - single coughs. Data from baseline 2 and pre-training were averaged for the pre--training value.
Measured: Baseline 2 (week 2), Pre-training (week 3), Post-Training (week 10)
Change From Baseline to Post-Treatment in Utterance Length
Change in utterance length (# of syllables produced on one breath) throughout the study duration. Participant read the Rainbow Passage and data were collected from this task.
Measured: Baseline 1 (week 1) and Post-Training (week 10)
Change From Baseline to Post-Treatment in Number of Pauses
Change in the total number of pauses that included breathing (breath pauses). Participant read the Rainbow Passage and data were collected from this task.
Measured: Baseline 1 (week 1) and Post-Training (week 10)
Change From Baseline to Post-Treatment in Syntactic Location of Pauses
Change in the location of pauses while breathing produced while reading. We determined where participants took breaths while reading the Rainbow Passage and categorized them according to syntax. Categories included at a major boundary (at the end of an independent clause marked by a period) and at a boundary that is not related to syntax (not a major or minor syntactical location). The number of pauses at each category of boundaries were converted to a percent of the total breaths taken while reading the passage.
Measured: Baseline 1 (week 1) and Post-Training (week 10)
Telehealth Satisfaction
Participants rated 15 statements with a 5-point Likert scale ranging from strongly disagree (1) to strongly agree (5). Example statements include: I can easily talk to my health-care provider, I can hear my health-care provider clearly, I can see my health-care provider as if we met in person, I think the care provided via telemedicine is consistent, and I receive adequate attention, telemedicine provides for my health care need, and overall, I am satisfied with the quality of service being provided via telemedicine. Total scores range from 0-75 and individual statement scores ranged from 1-5, with higher scores indicating higher satisfaction with the telepractice modality.
Measured: Post-Training (week 10)
Change From Pre-Training to Post-Training in Communication Participation Item Bank
Participants were instructed to use a 4-point Likert scale (3: not at all; 2: a little; 1: quite a bit; 0: very much) to rate if/how their ALS impacts ten hypothetical communicative situations. Participants total scores were then added together, ranging from 0-30, and converted to a T-score ranging from 24.2-71.0. High scores are more favorable, indicating that the participant feels that ALS impacts their communicative participation less than those with lower scores.
Measured: Pre-Training (week 3) and Post-Training (week 10)
Change From Baseline to Post-Treatment in ALS Quality of Life Scale
The ALS Quality of Life Scale-Revised (ALSQOL-R) (Simmons, 2015) was used to measure how ALS impacts their quality of life in six domains: negative emotion, interaction with people and the environment, intimacy, religiosity, physical symptoms, and bulbar function. Participants rate whether they strongly disagree (0) or strongly agree (10) with 46 statements. Each domain score is given an average value between 0 (worse) and 10 (best). Total scores on the ALSQOL-R range from 0-460, but an average score ranging from 0-10 is computed by dividing the total score by the total number of items completed by the participant (usually 46). Higher scores reflect a higher quality of life. A survey assessing how each participant feels ALS impacts quality of life, and how that changes throughout the study duration. Total scores range from 0-460, with higher scores indicating greater contributions of ALS to quality of life.
Measured: Baseline 1 (week 1) and Post-Training (week 10)
ALS Function Rating Scale Revised
A survey that quantifies change in disease progression throughout the study duration. Participants rate how 12 physical functions are impacted by their ALS. For each function, participants are provided with a 4-point Likert scale to rate whether they still have complete control of that function (4) or no ability to perform that function (0). Total scores range from 0 to 48, with lower scores indicating more severe symptoms and higher scores and less severe symptoms.
Measured: Baseline 1 (week 1) and Post-Training (week 10)
Psychosocial Impact of Assistive Devices Scale
A survey assessing how the training device/modality impacts patient's psychosocial functions. The PIADS includes 12 items for competence, 6 for adaptability, and 8 for self-esteem. Participants use a 7-point Likert scale to rate the impact of a device on each item: a maximum negative impact (-3), somewhat negative impact (-2 or -1), zero impact (0), somewhat positive impact (1 or 2), maximum positive impact (3). Total scores range from -78 (maximum negative impact) to 78 (maximum positive impact).
Measured: Post-treatment (week 10)
Tele-health Session Attendance
% of training sessions scheduled and attended by participants throughout the study duration
Measured: Measured at the end of training across the entire training period
Adherence to Training Protocol
Number of of training exhalations completed (25 exhalations into the device, 5 days per week) by participants throughout the study duration
Measured: Measured each week of training across the entire training duration
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted12 Aug 2021
- Study start1 Jan 2021
- Primary completion1 Jun 2022
- Study completion1 Jun 2022
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Other trials for Amyotrophic Lateral SclerosisStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Model description
- All participants enrolled will receive the intervention.
- Masking
- None (open label)
- Enrolment
- 13 participants (actual)
Sponsor and investigators
- Lead sponsor
- Purdue University
- Sponsor type
- University, hospital or other
- Collaborators
- National Institute on Deafness and Other Communication Disorders (NIDCD)
- Responsible party
- Principal investigator, HuberLab, Purdue University
- Investigators
- Jessica E Huber, Ph.D., Principal investigator, Purdue University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05003167
- Sponsor's protocol ID
- IRB-2020-524
- Other IDs
- 1F31DC019281-01
- Status last verified
- Jun 2023
- First submitted
- 6 Jul 2021
- Last updated
- 8 Jun 2023
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- Yes
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 8 Jun 2023. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Effectiveness of Expiratory Muscle Strength Training for Improving Communication in ALS
- ClinicalTrials.gov ID
- NCT05003167
- Acronym / sponsor ID
- IRB-2020-524
- Conditions
- Amyotrophic Lateral Sclerosis
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 13 participants (actual)
- Lead sponsor
- Purdue UniversityUniversity, hospital or other
- Collaborators
- National Institute on Deafness and Other Communication Disorders (NIDCD)
- Study start
- 1 Jan 2021 (actual)
- Primary completion
- 1 Jun 2022 (actual)
- Study completion
- 1 Jun 2022 (actual)
- First posted
- 12 Aug 2021 (actual)
- Results
- Posted 8 Jun 2023
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
A tele-health treatment study for individuals with early stage ALS with the aim to improve communication, cough response, and respiratory strength. All participants complete a respiratory strength training program using an Expiratory Muscle Strength Training (EMST 150) device from the comfort of their homes for 6 weeks.
Detailed description
The investigators are looking for people with early stage ALS to participate in a completely tele-health (no in-person visits required) treatment study examining the effects of an Expiratory Muscle Strength Training device (EMST-150) on communication, cough, and respiratory strength. Participants will be required to attend 2 virtual baseline assessment sessions followed by 12 additional virtual training sessions (2 per week for 6 weeks). Participants should plan to be actively enrolled in the study for ~10 weeks (3 weeks of baseline monitoring followed by 6 weeks of training). Participants will also be required to fill out a series of questionnaires assessing the EMST's effectiveness via tele-health.
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
- Model description
- All participants enrolled will receive the intervention.
| Arm | Type | Receives |
|---|---|---|
| Expiratory Muscle Strength Training | Experimental | Device: Expiratory Muscle Strength Training (EMST-150)All participants will forcefully breathe out into an Expiratory Muscle Strength Training device (EMST-150) 25 times per day for 6 weeks. The EMST device will be set at a moderate intensity level (50% of each participant's maximum expiratory pressure). |
Who may qualify
- Ages
- 40 to 70 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (5 listed)
- Diagnosis of ALS
- Within the early stages of disease progression (i.e., able to talk, breathe, and eat independently)
- Speaker of English
- Have a family member/caregiver willing to assist as needed
- Have access to an electronic device and internet for tele-health
Key exclusion criteria (5 listed)
- A history of neurological disease (besides ALS)
- A history of asthma or respiratory problems (e.g., COPD, emphysema)
- A history of head, neck, or chest surgery (except mastectomy)
- A history of smoking within the last 5 years
- Reliance on mechanical ventilation (including CPAP)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Expiratory Muscle Strength Training (EMST-150)All participants will forcefully breathe out into an Expiratory Muscle Strength Training device (EMST-150) 25 times per day for 6 weeks. The EMST device will be set at a moderate intensity level (50% of each participant's maximum expiratory pressure). | Device | Expiratory Muscle Strength Training |
Primary outcome
Change From Baseline to Post-treatment for Maximum Expiratory Pressure
Time frame: Baseline 2 (week 2), Pre-Training (week 3), and Post-Training (week 10)
Change in expiratory muscle strength throughout the study duration measured by the participant blowing into a pressure meter
11 secondary outcomes
Peak Expiratory Flow Rate
Time frame: Baseline 2 (week 2), Pre-training (week 3), Post-Training (week 10)
Change From Baseline to Post-Treatment in Utterance Length
Time frame: Baseline 1 (week 1) and Post-Training (week 10)
Change From Baseline to Post-Treatment in Number of Pauses
Time frame: Baseline 1 (week 1) and Post-Training (week 10)
Change From Baseline to Post-Treatment in Syntactic Location of Pauses
Time frame: Baseline 1 (week 1) and Post-Training (week 10)
Telehealth Satisfaction
Time frame: Post-Training (week 10)
Change From Pre-Training to Post-Training in Communication Participation Item Bank
Time frame: Pre-Training (week 3) and Post-Training (week 10)
Change From Baseline to Post-Treatment in ALS Quality of Life Scale
Time frame: Baseline 1 (week 1) and Post-Training (week 10)
ALS Function Rating Scale Revised
Time frame: Baseline 1 (week 1) and Post-Training (week 10)
Psychosocial Impact of Assistive Devices Scale
Time frame: Post-treatment (week 10)
Tele-health Session Attendance
Time frame: Measured at the end of training across the entire training period
Adherence to Training Protocol
Time frame: Measured each week of training across the entire training duration
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 8 Jun 2023.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
- Individual participant dataSharing planned: No
Related trials for Amyotrophic Lateral Sclerosis
RecruitingPhase 1/2
Study is to Assess the Safety and Tolerability of VTx-002 in Participants With ALS
Amyotrophic Lateral Sclerosis
Not yet recruiting
A Study on the Addition of Alsum30 for the Treatment of Amyotrophic Lateral Sclerosis
Amyotrophic Lateral Sclerosis (ALS), Bacillus Coagulans
Active, not recruiting
Functional Outcomes and Control Using Synchron BCI - Australia
Neurologic Disorder, Neurologic Diseases
Not yet recruitingPhase 1
Safety, Tolerability, and Pharmacodynamic Exploration of Orelabrutinib in Patients With Amyotrophic Lateral Sclerosis (ALS)
Amyotrophic Lateral Sclerosis (ALS)
Recruiting
Clinical Outcome Assessment for AT & BCI
Spinal Cord Injury, ALS (Amyotrophic Lateral Sclerosis)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Jessica E Huber, Ph.D. principal investigator
Purdue University
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Expiratory Muscle Strength Training (EMST-150) in people with Amyotrophic Lateral Sclerosis, run by Purdue University at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 8 Jun 2023. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Yes. Results are posted in the registry (first posted 8 Jun 2023). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change From Baseline to Post-treatment for Maximum Expiratory Pressure (time frame: Baseline 2 (week 2), Pre-Training (week 3), and Post-Training (week 10)). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 8 Jun 2023.